EGFR and familial pancreatic carcinoma: In the past two decades, other than adjuvant chemotherapy treatment, such as folfirinox, and the combination of nab-paclitaxel with gemcitabine, only one additional drug has been approved to treat pancreatic cancer, namely, the epidermal growth factor receptor (EGFR) inhibitor erlotinib [136,137,138,139,140,141,142,143].